- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02356809
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, open, comparing clinical trial assessing the therapeutic efficacy of pl-vegf165 (Neovasculgen) in treating scleroderma-associated Raynaud's syndrome. Each patient of clinical group will undergo several intramuscular injections with a treatment dose of pl-vegf165 (Neovasculgen) in hand where digital ulcers locate. In the control group patients will receive only standard of care without gene therapy drug.
Study participants at the first study visit will complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive capillaroscopy. After this initial assessment, the patients of clinical group will undergo intramuscular injections of pl-vegf165 (Neovasculgen) in a hand altered with digital ulcers.
Patient will report the severity of their Raynaud's symptoms weekly over the six month study period. At three month post-injection, the patient will complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive capillaroscopy. At six months post-injection, the patient will again complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive capillaroscopy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation
- Human Stem Cell Institute
-
Contact:
- Igor Plaksa
- Phone Number: +79112171859
- Email: i.plaksa2014@yandex.ru
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- obtained voluntary informed consent for participation in the clinical study
- presence of systemic scleroderma features satisfied to criteria of American College of Rheumatology classification
- presence at least one active digital ulcer at baseline
Exclusion Criteria:
- presence of another systemic connective tissue disease;
- absence at least one active digital ulcer at baseline;
- smoking within 3 months or smoking cessation using nicotine products;
- subjects currently taking sildenafil, tadalafil or vardenafil;
- history of sympathectomy over previous 12 months
- not able or unwilling to give voluntary informed consent for the study or follow requirements of the clinical study;
- decompensated chronic visceral diseases;
- clinically significant laboratory abnormalities;
- HIV, HBV and HCV antibodies in serum;
- alcohol or drug addiction;
- participation in other clinical studies (or administration of study products) within 3 months prior the study;
- conditions limiting study compliance (dementia, psycho-neurological diseases, drug addiction, alcoholism, etc.);
- malignancies including post-surgical period with chemo- and (or) radiation therapy);
- vascular malformations;
- pregnancy or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pl-vegf165
Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
|
Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance.
The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration.
The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
|
No Intervention: standard care
Patients of this group will receive standard therapy accepted in a clinical centre
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of new digital ulcers
Time Frame: 180 days
|
To determine the ability of pl-vegf165 to prevent development of new digital ulcers the frequency of new digital ulcers will be measured in both groups and then compared
|
180 days
|
Frequency of adverse events
Time Frame: 180 days
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of complete healing of digital ulcers
Time Frame: 180 days
|
The ability of pl-vegf165 to accelerate the healing of the digital ulcer will be measured by estimating the area of the defect in progress
|
180 days
|
Pain scores on the visual analog scale
Time Frame: 180 days
|
Visual analog scale is a diagnostic tool providing an assessment of the severity and quality of pain experienced by patients.
|
180 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Raynaud's Phenomenon
-
University Hospital, GrenobleCompletedHealthy | Raynaud's Phenomenon Isolated Primary | Raynaud's Phenomenon (Secondary)France
-
Covis Pharma S.à.r.l.CompletedRaynaud's Phenomenon Secondary to Connective Tissue DiseaseUnited States
-
ActelionCompletedRaynaud's Phenomenon Secondary to Systemic SclerosisGermany, France, United Kingdom
-
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...CompletedRaynaud's Phenomenon Secondary to Systemic SclerosisUnited States
-
Eicos Sciences, Inc.CompletedRaynaud's Phenomenon Secondary to Systemic SclerosisUnited States
-
University of Toledo Health Science CampusElectroCore INCTerminatedRaynaud Disease | Raynaud Phenomenon | Primary Raynaud Phenomenon | Raynaud SyndromeUnited States
-
University of Central FloridaTerminatedRaynaud PhenomenonUnited States
-
University of NottinghamCompleted
-
University Medical Center GroningenRecruiting
-
University Hospital, GrenobleUniversity Hospital, RouenRecruitingRaynaud PhenomenonFrance
Clinical Trials on Neovasculgen
-
Human Stem Cell Institute, RussiaCompletedLower Limb IschemiaRussian Federation
-
Human Stem Cell Institute, RussiaCompletedPeripheral Arterial DiseaseRussian Federation
-
Human Stem Cell Institute, RussiaKazan Federal UniversityUnknown
-
Human Stem Cell Institute, RussiaRyazan State Medical University; Vidnoe District HospitalCompletedUlcers Related to Diabetic Foot SyndromeRussian Federation